natgillin/translations-raw huggingface dataset:
Table 9: Steady-State Pharmacokinetics of Atazanavir with ritonavir in HIV-Infected Pregnant Women in the Fed State
Tablica 9: Farmakokinetika atazanavira s ritonavirom u stanju dinamičke ravnoteže u trudnica zaraženih HIV-om u sitom stanju
Table 9: Summary of efficacy results – study MCL-002, intent-to-treat population
Tablica 9: Sažeti prikaz rezultata djelotvornosti – ispitivanje MCL-002, populacija predviđena za liječenje
Table 9: SVR in genotype 1b†-infected subjects¶
Tablica 9: SVR u ispitanika s infekcijom genotipom 1b†¶
Table 9: Symptom outcomes for GIOTRIF vs. erlotinib in trial LUX-Lung 8 (EORTC QLQ-C30 & QLQ-LC13)
Tablica 9: Ishodi vezani uz simptome za GIOTRIF naspram erlotiniba u ispitivanju LUX-Lung 8 (EORTC QLQ-C30 & QLQ-LC13)
Table 9: Undesirable effects reported with Pegasys monotherapy for HBV or HCV or in combination with ribavirin for HCV patients in clinical trials and post marketing
Tablica 9: Prijavljene nuspojave pri liječenju samo lijekom Pegasys u bolesnika oboljelih od HBV-a ili HCV-a ili pri kombiniranoj terapiji lijekom Pegasys i ribavirinom u bolesnika oboljelih od HCV-a tijekom kliničkih ispitivanja i nakon stavljanja lijeka u promet
Table A: Pharmacokinetic Parameters at Multiple Dose Levels after a Single Infusion of Oxyglobin
Tablica A: Farmakokinetički parametri pri razinama višestrukih doza nakon jedne infuzije Oxyglobina
Table A: Pharmacokinetic Parameters at Multiple Dose Levels after a Single Infusion of Oxyglobin
Tablica A: Farmakokinetički parametri pri razinama višestrukih doza nakon jedne infuzije proizvoda Oxyglobin
Table A: Schedule for dose titration*
Tablica A: Raspored titriranja doze
Table A: Schedule for dose titration*
Tablica A: Raspored za titraciju doze
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm - GEICAM study.
Sljedeća tablica prikazuje da je incidencija neutropenije stupnja 4, febrilne netropenije i neutropenijske infekcije smanjena u bolesnika koji su primali primarnu profilaksu s G-CSF nakon što je ona uvedena kao obavezna u TAC skupini – GEICAM studija.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm - GEICAM study.
Sljedeća tablica prikazuje da je incidencija neutropenije stupnja 4, febrilne neutropenije i neutropenijske infekcije smanjena u bolesnika koji su primali primarnu profilaksu s G-CSF nakon što je ona uvedena kao obavezna u TAC skupini – GEICAM studija.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm – GEICAM study.
Sljedeća tablica prikazuje da je incidencija neutropenije stupnja 4, febrilne netropenije i neutropenijske infekcije smanjena u bolesnika koji su primali primarnu profilaksu s G-CSF nakon što je ona uvedena kao obavezna u TAC skupini – GEICAM studija.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm – GEICAM study.
Sljedeća tablica prikazuje da je incidencija neutropenije stupnja 4, febrilne neutropenije i neutropenijske infekcije smanjena u bolesnika koji su primali primarnu profilaksu s G-CSF nakon što je ona uvedena kao obavezna u TAC skupini – GEICAM studija.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm-GEICAM study.
Sljedeća tablica prikazuje da je incidencija neutropenije stupnja 4, febrilne neutropenije i neutropenijske infekcije smanjena u bolesnika koji su primali primarnu profilaksu s G-CSF nakon što je ona uvedena kao obavezna u TAC skupini – GEICAM studija.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm-GEICAM study.
Sljedeća tablica prikazuje da je učestalost neutropenije stupnja 4, febrilne netropenije i neutropenijske infekcije smanjena u bolesnika koji su primali primarnu profilaksu s G-CSF nakon što je ona uvedena kao obavezna u TAC skupini – GEICAM studija.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm. – GEICAM study.
Sljedeća tablica prikazuje da je incidencija neutropenije stupnja 4, febrilne netropenije i neutropenijske infekcije smanjena u bolesnika koji su primali primarnu profilaksu s G-CSF nakon što je ona uvedena kao obavezna u TAC skupini – GEICAM studija.
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm. – GEICAM study.
Sljedeća tablica prikazuje da je incidencija neutropenije stupnja 4, febrilne neutropenije i neutropenijske infekcije smanjena u bolesnika koji su primali primarnu profilaksu s G-CSF nakon što je ona uvedena kao obavezna u TAC skupini – GEICAM studija.
Table of Adverse Reactions
Tablica s nuspojavama
Table on the inner lid Injection Record
Tablica na unutrašnjem poklopcu Bilježenje injekcija
Table on the inner lid Injection Record
Tablica na unutrašnjem poklopcu Bilježenje injekcije
Table1 Tabulated summary of adverse reactions.
Tablica 1 Tablični sažetak nuspojava
Table2 Response in adult CML studies
Tablica 2 Odgovor u ispitivanjima KML-a u odraslih
Table3 Chemotherapy regimen used in combination with imatinib
Tablica 3 Režim kemoterapije korišten u kombinaciji s imatinibom
Table6 Summary of related ADRs reported in patients treated with capecitabine in combination treatment in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy
Tablica 6 Sažetak povezanih nuspojava prijavljenih u bolesnika liječenih kapecitabinom u kombiniranom liječenju, a koje su dodatno primijećene uz one već zabilježene kod monoterapije kapecitabinom ili su se javljale s većom učestalošću od onih kod monoterapije kapecitabinom.
Table9 Key efficacy results for AIO KRK study
Tablica9 Ključni podaci o djelotvornosti ispitivanja AIO KRK
Table: Adverse drug reactions to delamanid
Tablica: Nuspojave na delamanid
Table: Protective efficacy against cholera in the Bangladesh study (per-protocol analysis)
Tablica: Zaštitna djelotvornost protiv kolere u ispitivanju u Bangladešu (analiza po protokolu)
Table: Risk factors for ATE
Tablica: Čimbenici rizika za ATE
Tables 1 and 2 display the frequency of adverse drug reactions from placebo-controlled clinical trials in Parkinson’s disease and another indication.
Tabele 1 i 2 pokazuju učestalost nuspojava u placebom kontroliranim kliničkim ispitivanjima kod Parkinsonove bolesti i drugih indikacija.
Tables 1 and 2 display the frequency of adverse drug reactions from placebo-controlled clinical trials in Parkinson’s disease and another indication.
Tablice 1 i 2 pokazuju učestalost nuspojava u placebom kontroliranim kliničkim ispitivanjima kod Parkinsonove bolesti i druge indikacije.
Tables 1 and 2 display the frequency of adverse drug reactions from placebo-controlled clinical trials in Parkinson’s disease and Restless Legs Syndrome.
Tabele 1 i 2 pokazuju učestalost nuspojava u placebom kontroliranim kliničkim ispitivanjima kod Parkinsonove bolesti i sindroma nemirnih nogu.
Tables 1 and 2 display the frequency of adverse reactions from placebo-controlled clinical trials.
Tablice 1 i 2 pokazuju učestalost nuspojava u placebom kontroliranim kliničkim ispitivanjima.
Tables 1 to 4 will be based on events reported from healthcare professionals only.
1 do 4 temeljit će se na događajima koje prijavljuju samo zdravstveni djelatnici.
Tables 12-13 display results of the primary efficacy and safety endpoint in relevant sub-populations:
Tablice 12 - 13 sažimaju rezultate s obzirom na primarne ishode djelotvornosti i sigurnosti u relevantnim podskupinama:
Tables 13-15 display details of key results in the overall population:
Tablice 13 - 15 sažimaju ključne rezultate studije za ukupnu populaciju:
Tables 16-18 display results of the primary efficacy and safety endpoint in relevant sub-populations:
Tablice 16 - 18 sažimaju rezultate s obzirom na primarne ishode djelotvornosti i sigurnosti u relevantnim podskupinama:
Tables 7, 8 and 9 show major, fatal and intracranial bleedings, respectively, by creatinine clearance category in NVAF patients in ENGAGE AF-TIMI 48.
Tablice 7, 8 i 9 pokazuju velika krvarenja, krvarenja sa smrtnim ishodom odnosno intrakranijalna krvarenja prema kategoriji klirensa kreatinina u bolesnika s NVAF-om u ispitivanju ENGAGE AF- TIMI 48.
Tables 9-11 display details of key results in the overall population:
Tablice 9 - 11 sažimaju ključne rezultate studije za ukupnu populaciju:
Tablet
30 tableta
tablet
oslobađanem
Tablet
Tablete
Tablet
Tablete.
Tablet administration
Primjena tablete
Tablet ADROVANCE 70 mg/2,800 IU tablets
Tableta ADROVANCE 70 mg/2800 IU tablete
TABLET BLISTER FOIL TEXT
TEKST ZA BLISTER TABLETA
Tablet coat
tablet dlaka
Tablet coat
tablete kose
Tablet coat for 5/10/15/20 mg film-coated tablets Hypromellose
Ovojnica tablete za 5/10/15/20 mg filmom obložene tablete hipromeloza
Tablet coat hypromellose (E464), macrogol 6000, titanium dioxide (E171), carnauba wax (E903).
Ovojnica tablete: hipromeloza (E464), makrogol 6000, titanijev dioksid (E171), karnauba vosak (E903).
Tablet coat Hypromellose Hydroxypropylcellulose Macrogol 8000 Titanium dioxide (E171)
Ovojnica tablete: hipromeloza hidroksipropilceluloza makrogol 8000 titanijev dioksid (E171)
Tablet coat Hypromellose Polysorbate 80
Ovojnica tablete hipromeloza polisorbat 80
Tablet coat:
Ovojnica tablete:
Tablet coat:
Tablet dlaka :
tablet coat: hypromellose, titanium dioxide (E 171), talc, macrogol 6000
ovojnica tablete: hipromeloza, titanijev dioksid (E 171), talk, makrogol 6000
Tablet coating
Ovojnica tablete Titanijev dioksid (E171)
Tablet coating
Ovojnica tablete:
Tablet coating (for 150 mg): Hypromellose, titanium dioxide (E171), yellow iron oxide, red iron oxide (E172), talc
Ovojnica tablete (za 150 mg): hipromeloza, titanijev dioksid (E171), žuti željezov oksid, crveni željezov oksid (E172), talk
Tablet coating (for 300 mg): Hypromellose, titanium dioxide (E171), talc
Ovojnica tablete (za 300 mg): hipromeloza, titanijev dioksid (E171), talk
Tablet coating (for 500 mg): Hypromellose, titanium dioxide (E171), yellow iron oxide, red iron oxide (E172), talc
Ovojnica tablete (za 500 mg): hipromeloza, titanijev dioksid (E171), žuti željezov oksid, crveni željezov oksid (E172), talk
Tablet coating for 150 mg/12.5 mg strength: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), iron oxide red, iron oxide yellow and iron oxide black.
Ovojnica za 150 mg/12,5 mg tablete: hipromeloza, titanijev dioksid, polietilenglikol 6000 (makrogol), polietilenglikol 400 (makrogol), crveni željezov oksid, žuti željezov oksid i crni željezov oksid.
Tablet coating for 300 mg/12.5 mg strength: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), iron oxide red, iron oxide yellow and iron oxide black.
Ovojnica za 300 mg/12,5 mg tablete: hipromeloza, titanijev dioksid, polietilenglikol 6000 (makrogol), polietilenglikol 400 (makrogol), crveni željezov oksid, žuti željezov oksid i crni željezov oksid.
Tablet coating for 300 mg/25 mg strength: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), iron oxide red, Indigotine (Indigo carmine aluminium lake FD&C blue #2) and iron oxide black.
Ovojnica za 300 mg/25 mg tablete: hipromeloza, titanijev dioksid, polietilenglikol 6000 (makrogol), polietilenglikol 400 (makrogol), crveni željezov oksid, indigotin (Indigo carmine aluminium lake FD&C plava #2) i crni željezov oksid.
Tablet coating for 5/10/15/20 mg film-coated tablets:
Ovojnica tablete za 5 mg/10 mg/15 mg/20 mg filmom obložene tablete:
Tablet coating Hypromellose Macrogol 400
Ovojnica tablete hipromeloza makrogol 400
Tablet coating hypromellose titanium dioxide (E171) talc
Ovojnica tablete hipromeloza titanijev dioksid (E171) talk
Tablet coating hypromellose, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), talc.
Ovojnica tablete hipromeloza titanijev dioksid (E171) žuti željezov oksid (E172) crveniželjezov oksid (E172) talk
Tablet Coating Triacetin
Ovojnica triacetin
Tablet coating:
Film ovojnica:
Tablet coating:
Ovojnica tablete
Tablet coating: hypromellose (3 mPa.s), titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172) and talc.
Ovojnica tablete: hipromeloza (3 mPa.s), titanijev dioksid (E171), žuti željezov oksid (E172), crveni željezov oksid (E172) i talk.
Tablet coating: Hypromellose (E464), iron oxide red (E172), lactose monohydrate, triacetin (E1518), titanium dioxide (E171)
Ovojnica tablete: Hipromeloza (E464), crveni željezov oksid (E172), laktoza hidrat, triacetin (E1518), titanijev dioksid (E171)
Tablet coating: hypromellose 6 cp, titanium dioxide (E171), macrogol 3350, colourants*
Ovojnica tablete: hipromeloza 6 cp, titanijev dioksid (E171), makrogol 3350, bojila
Tablet coating: Hypromellose Macrogol 400 Titanium dioxide Iron oxide yellow
Ovojnica tablete: hipromeloza makrogol 400 titanijev dioksid željezov oksid, žuti
Tablet coating: hypromellose, polydextrose, titanium dioxide (E171), quinoline yellow aluminium lake (E104), talc, maltodextrin, medium chain triglycerides and iron oxide yellow (E172).
Ovojnica tablete: hipromeloza, polidekstroza, titanijev dioksid (E171), quinoline yellow aluminium lake (E104), talk, maltodekstrin, trigliceridi srednje duljine lanca i željezov oksid žuti (E172).
Tablet coating: hypromellose, polydextrose, titanium dioxide (E171), talc, maltodextrin, medium chain triglycerides, iron oxide yellow (E172). carmine (E120), iron oxide red (E172).
Ovojnica tablete: hipromeloza, polidekstroza, titanijev dioksid (E171), quinoline yellow aluminium lake (E104), talk, maltodekstrin, trigliceridi srednje duljine lanca, željezov oksid žuti (E172), karmin (E120), željezov oksid crveni (E172).
Tablet coating: hypromellose, polyethylene glycol 6000, titanium dioxide (E171), iron oxide (E172), mica (E555).
Filmska ovojnica: hipromeloza, polietilenglikol 6000, titanijev dioksid (E171), željezov oksid (E172), mica (E555).
Tablet coating: lactose monohydrate (milk sugar), hypromellose (E464), triacetin (E1518), red iron oxide (E172) and titanium dioxide (E171),
Ovojnica tablete: laktoza hidrat (mliječni šećer), hipromeloza (E464), triacetin (E1518), crveni željezov oksid (E172) i titanijev dioksid (E171),
Tablet coating: lactose monohydrate (see section 2 ‘Clopidogrel/Acetylsalicylic acid Zentiva contains lactose’), hypromellose (E464), titanium dioxide (E171), triacetin (E1518), red iron oxide (E172)
Ovojnica tablete: laktoza hidrat (vidjeti dio 2. " Klopidogrel/acetisalicilatna kiselina Zentiva sadrži laktozu"), hipromeloza (E464), titanijev dioksid (E171), triacetin (E1518), crveni željezov oksid (E172)
Tablet coating: lactose monohydrate (see section 2 ‘Clopidogrel/Acetylsalicylic acid Zentiva contains lactose’), hypromellose (E464), titanium dioxide (E171), triacetin (E1518), yellow iron oxide (E172)
Ovojnica tablete: laktoza hidrat (vidjeti dio 2. " Klopidogrel/acetisalicilatna kiselina Zentiva sadrži laktozu"), hipromeloza (E464), titanijev dioksid (E171), triacetin (E1518), žuti željezov oksid (E172)
Tablet coating: Lactose monohydrate Hypromellose (E464)
Obloga tablete: Laktoza monohidrat Hipromeloza (E464)
Tablet coating: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), macrogol 4000, iron oxide red (E172), iron oxide yellow (E172) and indigo carmine aluminium lake (E132).
Ovojnica tablete: laktoza hidrat, hipromeloza (E464), titanijev dioksid (E171), makrogol 4000, crveni željezov oksid (E172), žuti željezov oksid (E172) i indigo carmine aluminium lake (E132).
Tablet coating: Macrogol 3350 Polyvinyl alcohol Talc
Obloga tablete: Makrogol 3350 Polivinilni alkohol Talk
Tablet coating: macrogol, glycerol monooleate, pharmaceutical glaze, calcium sulfate, microcrystalline cellulose, sucrose, titanium dioxide, poloxamer 188, -tocopherol, povidone, carnauba wax, ink-red opacode S-1-15095.
Ovojnica tablete: makrogol, glicerolmonooleat, sredstvo za oblaganje, kalcijev sulfat, mikrokristalična celuloza, saharoza, titanijev dioksid, poloksamer 188, -tokoferol, povidon, karnauba vosak, tinta crvena opakod S-1-15095.
Tablet coating: macrogol, hypromellose, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172).
Ovojnica tablete: makrogol, hipromeloza, titanijev dioksid (E171), žuti željezov oksid (E172), crveni željezov oksid (E172).
Tablet coating: Polydextrose (E1200) Titanium dioxide (E171) Hypromellose (E464) Macrogol 4000
Ovojnica tablete: polidekstroza (E1200) titanijev dioksid (E171) hipromeloza (E464) makrogol 4000
Tablet coating: polydextrose (E1200), titanium dioxide (E171), hypromellose (E464) and macrogol 4000.
Ovojnica tablete: polidekstroza (E1200), titanijev dioksid (E171), hipromeloza (E464) i makrogol 4000
Tablet coating: polydextrose, titanium dioxide, hypromellose and macrogol 4000.
Ovojnica tablete: polidekstroza, titanijev dioksid, hipromeloza i makrogol 4000.
Tablet coating: polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc, carmine (E120), brilliant blue FCF aluminum lake (E133), indigo carmine aluminum lake (E132)
ovojnica tablete: poli(vinilni alkohol), titanijev dioksid (E171), makrogol 3350, talk, boja carmine (E120), boja brilliant blue FCF aluminium lake (E133), boja indigo carmine aluminium lake (E132)
Tablet coating: Polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc and macrogol 3000.
Filmska ovojnica: polivinilni alkohol, titanijev dioksid (E171), crveni željezov oksid (E172), žuti željezov oksid (E172), talk i makrogol 3000.
Tablet coating: Polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc and macrogol 3000.
Ovojnica tablete: poli(vinilni alkohol), titanijev dioksid (E171), crveni željezov oksid (E172), žuti željezov oksid (E172), talk i makrogol 3000
Tablet coating: Polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc and macrogol 3000.
Ovojnica tablete: Poli(vinilni alkohol), titanijev dioksid (E171), crveni željezov oksid (E172), žuti željezov oksid (E172), talk i makrogol 3000.
Tablet coating: Titanium dioxide Hypromellose Macrogol 400 Iron oxide red
Ovojnica tablete: titanijev dioksid hipromeloza makrogol 400 željezov oksid, crveni
Tablet coating: titanium dioxide, hypromellose, macrogol 400, iron oxide yellow, polysorbate, quinoline yellow aluminium lake and indigo carmine aluminium lake.
Ovojnica tablete: titanijev dioksid, hipromeloza, makrogol 400, željezov oksid žuti, polisorbat, quinoline yellow aluminium lake i indigo carmine aluminium lake.
Tablet coating: titanium dioxide, polydextrose, hypromellose, triethyl citrate and macrogol 8000.
Ovojnica tablete: titanijev dioksid, polidekstroza, hipromeloza, trietilcitrat i makrogol 8000.
tablet container
premnik za tablete
Tablet container
Spremnik za tablete
Tablet container (HDPE)
Bočica (HDPE)
Tablet container (HDPE)
Bočica(HDPE)
Tablet container (HDPE)
Spremnik (HDPE)
tablet container (PP)
premnik za tablete (PP)
Tablet container – Lamivudine Teva Pharma B.V. 150 mg film-coated tablets
Spremnik za tablete – Lamivudin Teva Pharma B.V. 150 mg filmom obložene tablete
Tablet container – Lamivudine Teva Pharma B.V. 300mg film-coated tablets
Spremnik za tablete – Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete
Tablet container:
Spremnik za tablete:
Tablet container: 90 tablets
Spremnik za tablete 90 tableta
Tablet containers 2.5 mg 3 years.
Bočica s tabletama 2,5 mg 3 godine.
Tablet containers:
Spremnici s tabletama:
Tablet containers: 30, 90 and 250 tablets
Spremnici s tabletama: 30, 90 i 250 tableta
tablet contains 6 mg of mavacoxib.
tableta sadrži 6 mg mavakoksiba.
Tablet core
Jezga tablete
Tablet core
Jezga tablete:
Tablet core
Jezgra tablete laktoza hidrat
Tablet core
Jezgra tablete: laktoza hidrat
Tablet core
Manitol
Tablet core
Odrasli
Tablet core (white active and yellow placebo film-coated tablets) Lactose monohydrate
Jezgra tablete (bijele filmom obložene tablete s djelatnim tvarima i žute filmom obložene tablete placeba)
Tablet core - microcrystalline cellulose (E460(i)), croscarmellose sodium (E468), sodium starch glycolate, crospovidone (E1202), stearic acid (E570), magnesium stearate (E470b), hydroxypropyl cellulose (E463), silicon dioxide (E551)
Jezgra tableta – mikrokristalična celuloza (E460(i)), umrežena karmelozanatrij (E468), natrijev škroboglikolat, krospovidon (E1202), stearatna kiselina (E570), magnezijev stearat (E470b), hidroksipropilceluloza (E463), silicijev dioksid (E551)
Tablet core anhydrous lactose, croscarmellose sodium, hypromellose (3 mPa.s), microcrystalline cellulose, magnesium stearate.
Jezgra tablete bezvodna laktoza umrežena karmelozanatrij hipromeloza (3 mPa.s) mikrokristalična celuloza magnezijev stearat
Tablet core Copovidone
Jezgra tablete kopovidon laktoza hidrat
Tablet core Croscarmellose sodium Colloidal anhydrous silica Magnesium stearate Hydroxypropylcellulose
Jezgra tablete karmelozanatrij, umrežena silicijev dioksid, koloidni, bezvodni magnezijev stearat hidroksipropilceluloza
Tablet core Croscarmellose sodium Hydroxypropyl cellulose Lactose monohydrate Magnesium stearate Microcrystalline cellulose Sodium lauryl sulfate
Jezgra tablete karmelozanatrij, umrežena hidroksipropilceluloza laktoza hidrat magnezijev stearat celuloza, mikrokristalična natrijev laurilsulfat
Tablet core Croscarmellose sodium Microcrystalline cellulose Sodium laurilsulfate Hydroxypropylcellulose Lactose monohydrate Magnesium stearate
Jezgra tablete karmelozanatrij, umrežena celuloza, mikrokristalična natrijev laurilsulfat hidroksipropilceluloza laktoza hidrat magnezijev stearat
Tablet core Crystalline Maltose
Jezgra tablete
Tablet core Hypromellose (E464), maize starch, crospovidone (E1202), poloxamer 407, lactose monohydrate, colloidal anhydrous silica, magnesium stearate(E572).
Jezgra tablete: hipromeloza (E464), kukuruzni škrob, krospovidon (E1202), poloksamer 407, laktoza hidrat, silicijev dioksid, koloidni, bezvodni, magnezijev stearat (E572).
Tablet core hypromellose microcrystalline cellulose lactose monohydrate crospovidone type A magnesium stearate
Jezgra tablete hipromeloza mikrokristalična celuloza laktoza hidrat krospovidon tipa A magnezijev stearat
Tablet core Hypromellose phthalate Povidone all-rac-α-Tocopherol Cellulose, microcrystalline
Jezgra tablete hipromelozaftalat povidon
Tablet core Hypromellose, 2910 Croscarmellose sodium Lactose monohydrate Silicon dioxide, colloidal Magnesium stearate Microcrystalline cellulose
Jezgra tablete hipromeloza 2910 karmelozanatrij, umrežena laktoza hidrat silicijev dioksid, koloidni magnezijev stearat celuloza, mikrokristalična
Tablet core Magnesium stearate Mannitol (E421)
Jezgra tablete magnezijev stearat manitol (E421)
Tablet core Mannitol
Jezgra tablete manitol
Tablet core mannitol (E421) cellulose microcrystalline (E460) croscarmellose sodium (E468) magnesium stearate (E470b) propyl gallate (E310)
Jezgra tablete manitol (E421) celuloza, mikrokristalična (E460) karmelozanatrij, umrežena (E468) magnezijev stearat (E470b) propilgalat (E310)
Tablet core Mannitol (E421), maize starch,
Jezgra tablete Manitol (E421), kukuruzni škrob,
Tablet core Microcrystalline cellulose Lactose monohydrate Croscarmellose sodium Magnesium stearate.
Jezgra tablete celuloza, mikrokristalična laktoza hidrat karmelozanatrij, umrežena magnezijev stearat